Ziopharm Oncology to Present at the BofA Securities 2020 Health Care Conference
BOSTON, May 08, 2020 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020, at 5:00 p.m. ET.
An audio webcast of the fireside chat will be available live, which can be accessed in the “Investors” section of the Ziopharm website at . A recording of the webcast will be available on the Company’s website until August 12, 2020.
About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit
Investor Relations Contacts:
Ziopharm Oncology:
Chris Taylor
VP, Investor Relations and Corporate Communications
T: 617.502.1881
E:
LifeSci Advisors:
Mike Moyer
Managing Director
T: 617.308.4306
E:
Media Relations Contact:
LifeSci Communications:
Patrick Bursey
T: 646.876.4932
E:
